

Brief Intervention for Anxiety in Primary Care Patients

Peter Roy-Byrne, MD, Jason P. Veitengruber, MD, Alexander Bystriksky, MD, Mark J. Edlund, MD, PhD, Greer Sullivan, MD, Michelle G. Craske, PhD, Stacy Shaw Welch, PhD, Raphael Rose, PhD, and Murray B. Stein MD, MPH

To address the difficulty of assessing and managing multiple anxiety disorders in the primary care setting, this article provides a simple, easy-to-learn, unified approach to the diagnosis, care management, and pharmacotherapy of the 4 most common anxiety disorders found in primary care: panic, generalized anxiety disorders, social anxiety disorders, and posttraumatic stress disorder. This evidence-based approach was developed for an ongoing National Institute of Mental Health-funded study designed to improve the delivery of evidence-based medication and psychotherapy treatment to primary care patients with these anxiety disorders. We present a simple, validated method to screen for the 4 major disorders that emphasizes identifying other medical or psychiatric comorbidities that can complicate treatment; an approach for initial education of the patient and discussion about treatment, including provision of some simple cognitive behavioral therapy skills, based on motivational interviewing/brief intervention approaches previously used for substance use disorders; a validated method for monitoring treatment outcome; and an algorithmic approach for the selection of initial medication treatment, the selection of alternative or adjunctive treatments when the initial approach has not produced optimal results, and indications for mental health referral. (J Am Board Fam Med 2009;22:175–186.)

In any given year, 18% of people will suffer from an anxiety disorder.¹ The majority of these individuals receive treatment in general medical rather than specialty mental health settings.² Anxiety disorders are as disabling as depressive disorders³ and generate increased costs because the physical manifestations of anxiety often prompt expensive diagnostic procedures.⁴ In primary care, only a small minority of anxious patients receive treatment targeting their anxiety.⁵

Studies suggest that the poor quality of care for anxiety in primary care may be related to difficulty recognizing and diagnosing anxiety disorders,^{6,7} the increased time and enhanced skill needed to optimally engage such patients in care,⁸ and a low perceived need for psychiatric treatment among patients.⁹ However, an even greater barrier to the effective delivery of evidence-based care for anxiety is the nonunitary nature of anxiety disorders: instead of having one depressive disorder (major de-

This article was externally peer reviewed.

Submitted 24 April 2008; revised 15 July 2008; accepted 22 July 2008.

From the Department of Psychiatry and Behavioral Sciences (PRB, JPV, SSW), University of Washington School of Medicine, Harborview Center for Healthcare Improvement for Addictions, Mental Illness and Medically Vulnerable Populations (CHAMMP), Seattle; the Department of Psychiatry and Biobehavioral Sciences (AB) and the Department of Psychology (MGC, RR), University of California, Los Angeles; the Department of Psychiatry (MJE, GS), University of Arkansas for Medical Sciences, Little Rock; and the Department of Psychiatry (MBS), University of California, San Diego.

Funding: This manuscript was supported by grants MH057858 (PRB), MH070022 (GS), MH058915 (MGC), and MH057835 (MBS) from the National Institutes of Health, Bethesda, MD.

Conflict of interest: Dr. Roy-Byrne reports he was a consultant for Jazz Pharmaceuticals and Solvay Pharmaceuti-

cals, and received CME and speaker honoraria from Wyeth-Ayerst Pharmaceuticals and Forest Laboratories. Dr. Bystriksky reports he was a consultant, speaker honoraria, and on the speaker's bureau for Jazz Pharmaceuticals. Dr. Stein reports receiving research support from Eli Lilly and Company and GlaxoSmithKline, and was a consultant for AstraZeneca, Avera Pharmaceuticals, BrainCells Inc., Bristol-Myers Squibb, Eli Lilly and Company, EPI-Q Inc., Forest Laboratories, Hoffmann-La Roche Pharmaceuticals, Integral Health Decisions Inc., Jazz Pharmaceuticals, Johnson & Johnson, Mindsite, Sanofi-Aventis, Transcept Pharmaceuticals Inc., and Virtual Reality Medical Center. The remaining authors have no interests to disclose. None of the entities mentioned above sponsored or had any role or influence in the preparation of this manuscript.

Corresponding author: Peter Roy-Byrne, MD, Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine at Harborview Medical Center, 325 9th Ave, Box 359911, Seattle, WA 98104 (E-mail: roybyrne@u.washington.edu).

pression) to diagnose and treat, primary care physicians are faced with multiple anxiety disorders (eg, panic disorder [PD], generalized anxiety disorder [GAD], social anxiety disorder [SAD], and posttraumatic stress disorder [PTSD]). This multiplicity of disorders makes it hard to have any unitary traction for public health education efforts; physicians must remember 4 different diagnostic and treatment approaches and, with the multitude of other problems they manage, this array of diagnostic algorithms and treatment options can become quite daunting.

This article provides a unified approach to the diagnosis, care management, and pharmacotherapy of primary care anxiety. We focus on the 4 most common anxiety disorders, all of which have an annual prevalence in primary care of between 5% and 10%, and cumulative rates for any of these between 10% and 15%.^{10–14} We developed this simple, easy-to-learn approach as part of an ongoing National Institute of Mental Health-funded study designed to improve the delivery of evidence-based medication and psychotherapy treatment to primary care patients with these anxiety disorders.¹⁵

We present a simple, validated method to screen for the 4 major disorders. The method emphasizes the identification of other medical or psychiatric comorbidities that can complicate treatment; an approach for the initial education of the patient and discussion about treatment based on motivational interviewing/brief intervention approaches previously used for substance use disorders¹⁶; a validated method for monitoring treatment outcome; and an algorithmic approach for the selection of initial medication treatment and the selection of alternative or adjunctive treatments when the initial approach has not produced optimal results. The entire procedure is outlined in Table 1 and, for each step, a strength of recommendation is provided based on the recent Strength of Recommendation Taxonomy criteria recommended for family medicine journals.¹⁷

Screening and Assessment

The assessment should determine which anxiety disorders are present; what other conditions (eg, depression, substance abuse, or pain) accompany it; which treatments have been tried in the past; and what the patient expects of treatment. Although

performing a comprehensive diagnostic interview is not practical, asking a single question about each of the 4 common anxiety disorders is simple, quick, and sensitive.¹⁸ Asking 2 simple questions about mood and anhedonia to check for depression (a positive answer to either suggests major depression) may be as effective as using longer instruments.^{19,20} The 3-item Alcohol Use Disorders Identification Test-C is highly sensitive for problem alcohol use,²¹ with cutoff scores of 6 for men and 4 for women indicating problem use, and a single 0 to 10 analog item asking about pain has been previously validated.²² This brief screening battery (Appendix 1) will suggest how many of the 4 anxiety disorders are present and if major depression, problem alcohol use, or chronic pain are also issues. Patients screening positive for panic attacks might have them cued by social situations (SAD) or traumatic memories (PTSD), so a follow-up question about whether they occur when the patient is alone and if they were unexpected can be useful in clarifying whether PD is present.

All anxious patients, whether or not they also have depression, should be assessed for current thoughts of active self-harm, passive thoughts of being “better off dead,” and a history of suicide attempts.²³ Ask patients with suicidal thoughts whether they have a plan, access to means (ie, firearms or stockpiled medications), or “reasons for living” that would stop them from acting.²⁴ Caution them that substance abuse increases risk for suicide. Patients unable to both contract for safety and agree to a specific safety plan should be referred to mental health professionals for evaluation.

A patient who has failed to respond to several antidepressants and has a mixture of anxiety and depressive symptoms could be suffering from an unrecognized bipolar illness.²⁵ Such patients may also complain of overstimulation with antidepressants and may report brief positive responses to these agents that rapidly wane. This is a difficult diagnosis to make because it often requires multiple observations over a period of time to confirm retrospective reports of mood fluctuations. Patients endorsing fewer than 7 of 13 yes/no items on the Mood Disorder Questionnaire²⁶ are highly unlikely to have bipolar illness, but scores higher than 7 detect fewer than half the cases.²⁷ Hence, consultation with a psychiatrist is usually the most prudent option.

Table 1. Assessment and Treatment Approach, with Strength of Recommendation Taxonomy Levels A, B, C

Clinical Focus	SORT Criteria ¹⁷	Assessment and Treatment Approach
Screening and Assessment	B	Four anxiety disorder questions: ADD
	A	Two depression questions
	A	Alcohol screen: AUDIT-C
	C	Pain: one question
	B	Suicide evaluation: thoughts, plan, intent, reasons for living
	B	Bipolar disorder: MDQ good specificity, poor sensitivity
Severity of Anxiety	A	GAD-7: symptom severity
	B	OASIS: functional impairment plus global symptoms
Treatment History	C	Specify response: little, moderate, a lot
Engaging the Patient-Brief Intervention	B	Expectations for outcome: 0–10
	B	Expectation for role in outcome: 0–10
	C	Use these and MI techniques
	C	Help patient weight positives/negatives
Education and Skills	C	Focus on avoidance: make list of avoided activities
	C	Cognitive restructuring to help with exposure
	C	Breathing techniques to help with exposure
	C	Exposure (easiest to hardest) over 8–12 weeks
Initial Medication	A	SSRI/SNRI: start low and go slow, but go
	B	Benzodiazepines: if >4 times per week, keep taking for 12 weeks, then taper slowly
	B	Benzodiazepines: may use as monotherapy in select cases
Treatment Resistant Anxiety	C	Add another antidepressant or benzodiazepine
	B	Consider in rare cases adding atypical neuroleptic
Medication Discontinuation	C	After 1 year of therapy
	C	Depending on comorbid psych and medical illness, avoidance, ongoing stress

ADD, Anxiety Depression Detector; AUDIT-C, Alcohol Use Disorder Identification Test; MDQ, Mood Disorders Questionnaire; GAD, generalized anxiety disorder; OASIS, Overall Anxiety Severity and Impairment Scale; MI, motivational interviewing; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin-norepinephrine reuptake inhibitor.

Anxiety severity can be measured with the GAD-7 scale, modeled after the now familiar Patient Health Questionnaire-9 scale for depression.^{28,29} A score above 10 suggests anxiety severity sufficient enough to consider treatment. Although this scale contains 6 GAD items and one PD-specific item, patients with other anxiety disorders also score high on this (see the scale at <http://www.healthandage.com/public/health-center/7/article/3308/gm=20!gid2=3129>). For measurement of functional impairment caused by anxiety, the 5-item Overall Anxiety Severity and Impairment Scale^{30,31} (OASIS) is ideal. In addition to the frequency and intensity of anxiety it measures the degree of avoidance and interference with work and social function, and has a cutoff score of 8 for clinically significant anxiety (see Appendix 2). Once done at baseline, these scales should be used to monitor treatment outcomes on subsequent visits

because multiple studies show that outcome improves with ongoing monitoring of treatment.^{32,33}

Ask patients whether they have had medication or psychotherapy treatment in the past for their anxiety and how helpful it has been. Because there are no standardized scales to determine this, ask whether a treatment has helped a little, moderately, or a lot (ie, returned them to their prior state). These questions correspond to frequently used measures in medication trials of “partial response” (25% improvement), “response” (50% improvement), and remission (75% to 100% improvement).³⁴ It is also important to know if treatment was stopped because of side effects and the nature of these. This is critical for anticipating problems with adherence. Finally, ask 2 simple questions about how much, on a scale of 0 (none) to 10 (definitely), the patient thinks treatment might work (“outcome expectancy”) and how confident

they are they can help the treatment along (self-efficacy expectancy). Both of these measures are powerful determinants of whether patients remain in treatment and whether they improve.^{35–38} If any problems with treatment adherence arise, these measures can be used productively in a follow-up counseling session with the physician or non-MD team members, using the motivational interviewing approach outlined below.

Managing the Initial Visit: A Brief Intervention

The goal of an initial visit is to establish an empathic working relationship by using motivational interviewing techniques and style^{16,39–41}; to give the patient feedback about their problem (what are the likely disorders and how does their anxiety severity fit in with population norms [based on GAD-7 norms]); to understand the patient's motivation for treatment; and to review possible barriers to treatment, whether psychological, social, or logistic. Once the patient is interested in pursuing treatment, the physician must help the patient see that making specific changes in behavior and thinking will speed improvement before prescribing medication. This state of "self-activation" can frame the medication treatment, improving its efficacy and the patient's adherence to it.

Avoiding an authoritarian and prescriptive approach with the anxious patient is essential because such a style inadvertently encourages repeated reassurance seeking and discourages self-activation; instead, the style is a blend of "supportive companion" and "knowledgeable consultant." It is best to reflect how the anxiety has adversely affected them (the "negatives" of being anxious) and help them to overcome whatever barriers might interfere with their pursuit of treatment (eg, logistic problems, concerns about taking medication, belief that treatment will not work). If the patient has low expectations that treatment will work (low "outcome expectancy") or that they can do much to help it along (poor "self-efficacy expectancy"), ask what might improve these expectancies and reinforce whatever strengths they have (eg, perseverance). Avoid arguing (roll with any resistance the patient shows),⁴¹ and instead help the patient develop an awareness of the discrepancy between where they are (all the "negatives" that go with anxiety) and where they would like to be (all the "positives" that

go with being anxiety free, what they would be able to do, etc). Some patients may not want to commit during an initial session, but laying the groundwork could make a repeat visit much easier. Available web sites detail this interviewing approach (<http://motivationalinterview.org/training/index.html#training>), which has been shown to enhance adherence and participation for psychiatric and medical disorders. Although best known for use in substance abuse treatment, there is increasing interest in using these techniques with anxiety disorders and evidence that it may increase efficacy and retention in cognitive behavioral treatment (CBT).^{42,43} Conceptualizing anxiety as a "behavior" (ie, it ultimately can be under a patient's control) rather than a "symptom" makes it easier to apply this approach. Avoidance is the major driver of all anxiety, fuels failures of motivation and self-activation, and promotes maladaptive coping strategies. Patients need to be gently encouraged to face their fears by decreasing avoidant behavior and adopting a more activated life approach. By describing these behaviors as what successful people do to get over anxiety, greater self-activation will become more attractive to the patient.

Providing Education and Simple Skills for Anxiety

Use this part of the session to frame medication treatment. For patients ambivalent about treatment, try this by itself and revisit the possibility of medication in a second visit. Educate patients about the "cycle of anxiety" (see Figure 1), which consists of a positive feedback cycle where anxious thoughts, physical symptoms, and avoidance behavior feed on one another and aggravate anxiety. Use the figure to illustrate that genetic vulnerability, stressful experiences, and maladaptive thoughts and habits all contribute to anxiety and hence both medications and habit change can be therapeutic. Understanding that anxiety is a normal human response that the patient is having trouble turning off when it is not needed helps normalize the reaction.⁴⁴

CBT approaches are used to interrupt this cycle and typically require at least 6 to 8 sessions. Although it has not been formally investigated, introducing these CBT principles into the primary care visit could be effective; previous studies have found a single educational session can be beneficial.⁴⁵




Figure 1. Cycle of anxiety.

Here we provide some simple educational guidelines that address the behavioral, cognitive, and physical manifestations of anxiety and are discussed in more detail in standard textbooks.⁴⁴

Behavioral avoidance can be directly counteracted by gradual exposure to feared objects or situations.⁴⁶ Encourage the patient to make a list of their most feared situations (from least feared to most feared) and suggest they gradually try to face these situations, starting with the easiest first (eg, social situations for SAD, reminders of trauma for PTSD, situations from which it is difficult to escape or help is not readily available for PD, and situations involving more self-reliance, for example, for GAD). If they take to this, it could well require 8 to 12 weeks to work through least feared to most feared. The most important point is for practice to be regular and daily with little interruption.

During exposure, cognitive distortions are likely to arise and need to be questioned with an open scientific mind.⁴⁷ The 2 most common errors made by anxious patients are overestimating the risk that something bad will happen (jumping to conclusions, eg, “if I feel lightheaded, I will faint”) or thinking that if something bad does happen the outcome will be terribly catastrophic (blowing

things out of proportion, eg, “I will panic while driving and will lose control of the car and crash”). Help patients understand that these thinking patterns are unrealistic (ie, these beliefs have rarely, if ever, been confirmed in real life) so they can develop more evidence-based appraisals. Some patients may be able to apply these simple principles themselves although many others are likely to need more coaching, which could be provided in brief follow-up sessions or through referral to a CBT expert.

Finally, physical symptoms of anxiety can be counteracted by relaxation techniques such as progressive muscle relaxation⁴⁸ and diaphragmatic breathing (put one hand on your belly, the other on your chest, and make only the hand on your belly move when you breathe; this should be practiced several times a day).⁴⁹ Regular exercise also contributes to counteracting physical symptoms of anxiety,^{50,51} as will avoidance of caffeine and alcohol and poor sleep hygiene, which can often aggravate anxiety. Addressing these lifestyle factors can often have a clear-cut effect. Finally, emphasize to patients that they do not need to totally eliminate anxious symptoms. Instead, they should develop an attitude that symptoms can be managed and even tolerated while they do something they were not

Table 2. Selective Serotonin Reuptake Inhibitor and Serotonin Norepinephrine Reuptake Inhibitor Antidepressant Options

Medication	Anxiolytic Efficacy*	Advantages	Disadvantages
Fluoxetine	Panic, [†] PTSD*	Generic available; long half life (no withdrawal)	Most stimulating; longer half life
Paroxetine	Panic, [†] GAD, [†] SAD, [†] PTSD [†]	Generic available; most extensively studied across these anxiety disorders; least stimulating; no P450 3A4 effects	Most sedating; shorter half life and worse withdrawal
Sertraline	Panic, [†] GAD,* SAD, [†] PTSD [†]	Well-studied across these 4 anxiety disorders; least P4502D6 effects; minimal P4503A4 effects; intermediate half life (less withdrawal)	Most diarrhea
Citalopram	Panic*	Generic available; no P450 effects	
Escitalopram	Panic,* GAD, [†] SAD*	No P450 effects	
Venlafaxine ER	Panic, [†] GAD, [†] SAD, [†] PTSD	No P450 effects, pain effects	Short half life; withdrawal with missed dose or sudden discontinuation; increased blood pressure at >225 mg
Duloxetine	GAD [†]	Pain effects	Unclear efficacy for other anxiety disorders; more stimulating

*Randomized controlled trials but no Food and Drug Administration-approved indication.

[†]Food and Drug Administration-approved indication as of January 2006.

GAD, generalized anxiety disorder; PTSD, posttraumatic stress disorder; SAD, social anxiety disorder.

able to do previously (eg, drive on the freeway). This helps establish realistic expectations about treatment.

Medication Approaches for Anxiety

Selecting the Agent and Adjusting the Dose

There are more similarities than differences in indicated medication treatments for the 4 most common anxiety disorders (PD, GAD, SAD, and PTSD). Although developed for depression, antidepressants are also anxiolytic and Food and Drug Administration-approved for these 4 anxiety disorders. Antidepressants are generally first-line pharmacotherapy, particularly because comorbid depression is common in such patients and because there is no abuse liability as there is with benzodiazepines. If a patient has never received medication treatment before, an selective serotonin reuptake inhibitor (SSRI) is recommended. SSRIs and the serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine XR are all equally efficacious for all 4 disorders.^{52,53} Data about the other serotonin-norepinephrine reuptake inhibitor duloxetine support efficacy in GAD but other disorders have not been studied. When choosing between them, the clinician and patient should focus on the cost and generic availability; the risk of break-

through symptoms when a dose is inadvertently missed (paroxetine and venlafaxine have the shortest half lives and produce more immediate withdrawal symptoms when a dose is missed, whereas fluoxetine is at the other end with a very long half-life and no risk of breakthrough symptoms); the ease of titration (venlafaxine requires more titration steps than SSRIs); the potential for CYP450-mediated interactions with other medications (citalopram, escitalopram, and venlafaxine have no CYP450 effects); and the risk of adverse effects, which are highly idiosyncratic. For this last issue, there is little definitive data because there are few comparative studies among SSRIs not biased by industry funding; the best study failed to show any differences in depressed patients,⁵⁴ and a smaller study showed similar negative findings in patients with anxious depression.⁵⁵ Furthermore, some adverse effects may be different in depressed as opposed to anxious patients. All medications with an SSRI effect, including venlafaxine, produce sexual dysfunction. These considerations are outlined in Table 2.

If there is a history of response to a different antidepressant, that antidepressant can be tried first. If there is a prior response to a benzodiazepine, an SSRI is still preferred. If there has been

prior nonresponse to an SSRI, use of a different SSRI is recommended. Determine whether previous medication trials were conducted for an adequate duration (minimum of 8 to 12 weeks) at an adequate dosage (whichever is reached first: the maximum suggested by the manufacturer or the maximally tolerated); in this setting the prescription of appropriate type of medication is common but doses are often too low.⁵⁶ Always start with a low dose, particularly with PD, but titrate up to average doses in 2 to 3 weeks as tolerated, and then to higher maximally tolerated doses by 6 weeks unless substantial response has occurred. Use the GAD-7 or Overall Anxiety Severity and Impairment Scale (OASIS) to monitor treatment and characterize trials as producing partial response, response, or remission. Consider using the scale for a week before initiating treatment because patients' tendency to attribute fluctuations in their anxiety to new medications will be discouraged by observing that natural fluctuations occur without being on medication.

What to Do about Benzodiazepines

Although coadministration of a benzodiazepine with an SSRI has been shown to speed response,⁵⁷ this strategy is not recommended routinely. However, if patients are taking regular daily doses of a benzodiazepine (more than 4 times a week), it is unwise to immediately taper medication. Start an antidepressant first, titrate up to a maximal dose, and wait 12 weeks to maximize the chance of response. Then, reduce the benzodiazepine dose gradually, by 10% to 20% at 2- to 4-week intervals.^{58–60} Substituting a long-acting benzodiazepine like clonazepam for short half-life medications may be useful in some patients. Patients will be more comfortable with an initial strategy of benzodiazepine dose reduction rather than benzodiazepine elimination. Once their anxiety improves and they see they can do well on reduced doses combined with an antidepressant, discontinuation is often much easier. However, adding a benzodiazepine to antidepressants is a commonly used and effective, but not formally studied, strategy for treatment-resistant anxiety^{61,62} (see below); some patients may require a benzodiazepine for therapeutic effect. Accordingly, elimination of the benzodiazepine may not be therapeutically appropriate in some cases.

If a patient has a history of nonresponse to several antidepressants, intolerance caused by overstimulation, other adverse effects, or concomitant medical illness or its treatment, the evidence base suggests that a benzodiazepine may be a reasonable agent to use as monotherapy provided that there is no current substance use problem, any history of substance use is remote or has been addressed in treatment, there is no current depression requiring treatment, and the anxiety syndrome is PD or SAD.⁵² Benzodiazepines have not been demonstrated to work for PTSD, although they are sometimes used to reduce hyperarousal, often in combination with other pharmacological therapies.⁶³ GAD as a stand alone diagnosis is difficult to make and may be confused with adult attention deficit hyperactivity disorder, personality disorder, occult unrecognized substance use disorder, or atypical bipolar illness with "mixed" state features. Hence, use of benzodiazepines targeted exclusively toward a GAD diagnosis is fraught with risks and requires added psychiatric consultation.

If benzodiazepines are to be used, alprazolam 2.0 to 6.0 mg daily (usually TID or QID) and lorazepam 4.0 to 12.0 mg daily (usually BID or TID) may be problematic because the multiple dosing required continually links pill taking with the need to cope with anxiety throughout the day. Instead, use high potency medications (clonazepam 1 to 4 mg daily, usually BID) because the long half-life will reduce the risk of withdrawal symptoms with missed doses. Clonazepam's slower rate of absorption also reduces abuse liability and it can be administered once daily, although BID use is more common. The cognitive effects of high potency benzodiazepines may be problematic.⁶⁴ Although elderly patients are clearly more vulnerable to this effect, the performance of younger individuals with jobs requiring complex information processing and multitasking also may be subtly compromised. A promising alternative to benzodiazepines, with less risk of abuse or physical dependence in studies so far, are GABAergic agents like gabapentin, which are shown to be effective for PD⁶⁵ and SAD⁶⁶ in small controlled trials, and pregabalin, now marketed for neuropathic pain and fibromyalgia and shown effective in controlled clinical trials for SAD and GAD.⁶⁷ These agents are not Food and Drug Administration-approved for use for anxiety but could be useful for treatment-resistant patients in whom benzodiazepines are contraindicated.

Anxiety Resistant to First-Line Treatment

Before exploring additional therapies, failure to respond should always prompt a reconsideration of the diagnosis. Are there other syndromes (eg, atypical bipolar disorder) that may account for this? Are there new life stressors or changes? Occult substance abuse may be playing a role. Patients may not reliably report their substance abuse early on, but may be more willing to describe their usage patterns once they are in treatment. It is therefore worthwhile to ask about substance use not only at the start of treatment but again later in treatment, especially if the patient is not responding as well as expected. Finally, functional status should be reassessed, especially avoidance, which may continue to persist despite symptom improvement and may require a more behavioral approach.

In the absence of controlled data to guide strategies for treatment-resistant anxiety, results of various strategies for treatment-resistant depression from the recent STAR-D study^{33,68–71} can be used as a guideline for antidepressant selection (though it has no data on benzodiazepines). For patients showing at least partial response (25% improvement in symptoms and/or function) with a maximum dose of an antidepressant, continue this agent while adding another medication. Adding a benzodiazepine is one option especially useful when there is a prominence of residual anxious symptoms without residual depressive symptoms.⁶² Alternatively, adding another antidepressant is useful and could include combining an SSRI with venlafaxine, or combining either agent with mirtazapine or a tricyclic antidepressant. The small risk of serotonin syndrome when these serotonin-active agents are combined needs to be considered. If depression is more prominent in the clinical picture, the addition of bupropion could be considered. Third-line medication augmentation could include addition of an atypical antipsychotic, a strategy that is supported by some small randomized trials.^{72–74} Although increased efficacy is likely with some of these atypical antipsychotics, the magnitude of the additional benefit is sometimes small to modest at best and the risk of adverse effects (eg, weight gain, diabetes [typically a type II and rarely type I], and dyslipidemia) requires careful consideration of the risk–benefit ratio in the individual patient.

Medication Discontinuation

Use of medication may serve in many patients as a “safety” signal that reinforces their feeling that they

cannot cope on their own or gradually master anxiety-provoking situations by exposing themselves and learning through actual experience that nothing terrible will happen. These “reverse CBT” effects may be particularly prominent with rapidly acting and tranquilizing benzodiazepines, which immediately reinforce the user with prompt reduction in anxiety, undercutting their own abilities to “toughen up” in the face of stress. In many patients considering discontinuation of medication after a period of remission, these issues can become prominent; patients who are more confident they can master stress on their own and weather anxious feelings are more likely to do well with medication discontinuation.

Decisions about discontinuing medication should be based on the probability of relapse once medication is stopped. This is greatest for patients with multiple disorders who have some remaining residual symptoms and/or patients who have ongoing medical or psychosocial stress. Patients with all these factors are likely to do poorly, and patients with none of these are likely to do well. Most patients will fall somewhere in between and their status with respect to these factors should be used to make individual decisions.

References

1. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry* 2005;62:617–27.
2. Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC. Twelve-month use of mental health services in the United States. Results from the National Comorbidity Survey Replication. *Arch Gen Psychiatry* 2005;62:629–40.
3. Stein MB, Roy-Byrne PP, Craske MG, et al. Functional impact and health utility of anxiety disorders in primary care outpatients. *Med Care* 2005;43:1164–70.
4. Katon W, Roy-Byrne P, Russo J, Cowley D. Cost-effectiveness and cost offset of a collaborative care intervention for primary care patients with panic disorder. *Arch Gen Psychiatry* 2002;59:1098–104.
5. Stein MB, Sherbourne CD, Craske MG, et al. Quality of care for primary care patients with anxiety disorders. *Am J Psychiatry* 2004;161:2230–7.
6. Nisenson LG, Pepper CM, Schwenk TL, Coyne JC. The nature and prevalence of anxiety disorders in primary care. *Gen Hosp Psychiatry* 1998;20:21–8.
7. Ormel J, Koeter MW, van den Brink W, van de Willige G. Recognition, management, and course of anxiety and depression in general practice. *Arch Gen Psychiatry* 1991;48:700–6.

8. Kroenke K, Jackson JL, Chamberlin J. Depressive and anxiety disorders in patients presenting with physical complaints: clinical predictors and outcome. *Am J Med* 1997;103:339–47.
9. Mojtabai R, Olfson M, Mechanic D. Perceived need and help-seeking in adults with mood, anxiety, or substance use disorders. *Arch Gen Psychiatry* 2002;59:77–84.
10. Stein MB, McQuaid JR, Pedrelli P, Lenox R, McCall ME. Posttraumatic stress disorder in the primary care medical setting. *Gen Hosp Psychiatry* 2000;22:261–9.
11. Leon AC, Olfson M, Broadhead WE, et al. Prevalence of mental disorders in primary care: implications for screening. *Arch Fam Med* 1995;4:857–61.
12. Sherbourne CD, Jackson CA, Meredith LS, Camp P, Wells KB. Prevalence of comorbid anxiety disorders in primary care outpatients. *Arch Fam Med* 1996;5:27–34.
13. Spitzer RL, Kroenke K, Williams JBW. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. *Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA* 1999;282:1737–44.
14. Kroenke K, Spitzer RL, Williams JB, et al. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. *Ann Intern Med* 2007;146:317–25.
15. Sullivan G, Craske MG, Sherbourne C, et al. Design of the Coordinated Anxiety Learning and Management (CALM) study: innovations in collaborative care for anxiety disorders. *Gen Hosp Psychiatry* 2007;29:379–87.
16. Miller WR, Rollnick S. *Motivational interviewing: preparing people to change addictive behavior*. New York: Guilford Press; 1991.
17. Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. *J Am Board Fam Pract* 2004;17:59–67.
18. Means-Christensen A, Sherbourne CD, Roy-Byrne PP, Craske MG, Stein MB. Using five questions to screen for five common mental disorders in primary care: the anxiety and depression detector (ADD). *Gen Hosp Psychiatry* 2006;28:108–18.
19. U.S. PSTF: Screening for Depression
20. Whooley MA, Avins AL, Miranda J, Browner WS. Case-finding instruments for depression. Two questions are as good as many. *J Gen Intern Med* 1997;12:439–45.
21. Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT-C as a brief screen for alcohol misuse in primary care. *Alcohol Clin Exp Res* 2007;31:1208–17.
22. Butt Z, Wagner LI, Beaumont JL, et al. Use of a single-item screening tool to detect clinically significant fatigue, pain, distress, and anorexia in ambulatory cancer practice. *J Pain Symptom Manage* 2008;35:20–30.
23. Sareen J, Cox BJ, Afifi TO, et al. Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. *Arch Gen Psychiatry* 2005;62:1249–57.
24. Linehan MM, Goodstein JL, Nielsen SL, Chiles JA. Reasons for staying alive when you are thinking of killing yourself: the reasons for living inventory. *J Consult Clin Psychol* 1983;51:276–86.
25. Simon NM, Otto MW, Wisniewski SR, et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). *Am J Psychiatry* 2004;161:2222–9.
26. Hirschfeld RM, Williams JB, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. *Am J Psychiatry* 2000;157:1873–5.
27. Phelps JR, Ghaemi SN. Improving the diagnosis of bipolar disorder: predictive value of screening tests. *J Affect Disord* 2006;92:141–8.
28. Lowe B, Decker O, Muller S, et al. Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. *Med Care* 2008;46:266–74.
29. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med* 2006;166:1092–7.
30. Campbell-Sills L, Norman SB, Craske MG, et al. Validation of a brief measure of anxiety-related severity and impairment: the Overall Anxiety Severity and Impairment Scale (OASIS). *J Affect Disord* 2008;112:92–101.
31. Norman SB, Cissell SH, Means-Christensen AJ, et al. Development and validation of an Overall Anxiety Severity And Impairment Scale (OASIS). *Depress Anxiety* 2006;23:245–9.
32. Katon W, Von Korff M, Lin E, Simon G. Rethinking practitioner roles in chronic illness: the specialist, primary care physician, and the practice nurse. *Gen Hosp Psychiatry* 2001;23:138–44.
33. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. *Am J Psychiatry* 2006;163:28–40.
34. Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. *J Clin Psychiatry* 2001;62(suppl 16):5–9.
35. Williams SL, Kinney PJ, Falbo J. Generalization of therapeutic changes in agoraphobia: the role of perceived self-efficacy. *J Consult Clin Psychol* 1989;57:436–42.
36. Safren SA, Heimberg RG, Juster HR. Clients' ex-

- pectancies and their relationship to pretreatment symptomatology and outcome of cognitive-behavioral group treatment for social phobia. *J Consult Clin Psychol* 1997;65:694–8.
37. Grilo CM, Money R, Barlow DH, et al. Pretreatment patient factors predicting attrition from a multicenter randomized controlled treatment study for panic disorder. *Compr Psychiatry* 1998;39:323–32.
38. Shear MK. Psychotherapeutic issues in long-term treatment of anxiety disorder patients. *Psychiatr Clin North Am* 1995;18:885–94.
39. Miller WR. Motivational interviewing: research, practice, and puzzles. *Addict Behav* 1996;21:835–42.
40. Miller WR, Baca C, Compton WM, et al. Addressing substance abuse in health care settings. *Alcohol Clin Exp Res* 2006;30:292–302.
41. Miller WR, Rollnick S. Motivational interviewing: Preparing people for change. 2nd edition. New York: Guilford Press; 2002.
42. Westra H, Dozois D. Preparing clients for cognitive behavior therapy: a randomized pilot study of motivational interviewing for anxiety. *Cognit Ther Res* 2006;30:481–98.
43. Slagla D, Gray M. The utility of motivational interviewing as an adjunct to exposure therapy in the treatment of anxiety disorders. *Prof Psychol Res Pr* 2007;38:329–37.
44. Barlow DH. Anxiety and its disorders: the nature and treatment of anxiety and panic. New York: Guilford Press; 2002.
45. Swinson RP, Soulios C, Cox BJ, Kuch K. Brief treatment of emergency room patients with panic attacks. *Am J Psychiatry* 1992;149:944–6.
46. Craske MG. Anxiety disorders: psychological approaches to theory and treatment. Boulder (CO): Westview Press; 1999.
47. Beck A, Emery G, Greenberg R. Anxiety disorders and phobias: a cognitive perspective. New York: Basic Books; 1985.
48. Ost L, Westling B. Applied relaxation vs cognitive therapy in the treatment of panic disorder. *Behav Res Ther* 1995;33:145–8.
49. Garssen B, Ruiter CD, Dyck RV, et al. Will hyperventilation syndrome survive: a responder to Ley. *Clinical Psychology Review* 1993;13:683–90.
50. Broman-Fulks JJ, Storey KM. Evaluation of a brief aerobic exercise intervention for high anxiety sensitivity. *Anxiety Stress Coping* 2008;21:117–28.
51. Strohle A, Feller C, Onken M, Godemann F, Heinz A, Dimeo F. The acute antipanic activity of aerobic exercise. *Am J Psychiatry* 2005;162:2376–8.
52. Roy-Byrne PP, Cowley D. Pharmacologic treatments for panic disorder, generalized anxiety disorders, specific phobia and social anxiety disorders. In: Nathan P, Gorman J, eds. A guide to treatments that work, 3rd edition. New York: Oxford University Press; 2007.
53. Stein MB. Anxiety disorders: somatic treatment. In: Sadock BJ, Sadock VA, eds. Comprehensive textbook of psychiatry, 8th edition. Baltimore (MD): Lippincott Williams & Wilkins; 2004.
54. Kroenke K, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. *JAMA* 2001;286:2947–55.
55. Fava M, Rosenbaum JF, Hoog SL, Tepner RG, Kopp JB, Nilsson ME. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. *J Affect Disord* 2000;59:119–26.
56. Roy-Byrne P, Russo J, Dugdale DC, Lessler D, Cowley D, Katon W. Undertreatment of panic disorder in primary care: role of patient and physician characteristics. *J Am Board Fam Pract* 2002;15:443–50.
57. Goddard AW, Brouette T, Almai A, Jetty P, Woods SW, Charney D. Early coadministration of clonazepam with sertraline for panic disorder. *Arch Gen Psychiatry* 2001;58:681–6.
58. Rickels K, Schweizer E, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. *Arch Gen Psychiatry* 1990;47:899–907.
59. Rickels K, Schweizer E, Csanalosi I, Case WG, Chung H. Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone. *Arch Gen Psychiatry* 1988;45:444–50.
60. Rickels K, Schweizer E, Weiss S, Zavodnick S. Maintenance drug treatment for panic disorder. II. Short- and long-term outcome after drug taper. *Arch Gen Psychiatry* 1993;50:61–8.
61. Pollack MH, Otto MW, Roy-Byrne PP, et al. Novel treatment approaches for refractory anxiety disorders. *Depress Anxiety* 2008;25:467–76.
62. Bystritsky A. Treatment-resistant anxiety disorders. *Mol Psychiatry* 2006;11:805–14.
63. Mellman TA, Clark RE, Peacock WJ. Prescribing patterns for patients with posttraumatic stress disorder. *Psychiatr Serv* 2003;54:1618–21.
64. Stewart SA. The effects of benzodiazepines on cognition. *J Clin Psychiatry* 2005;66(suppl 2):9–13.
65. Pande AC, Pollack MH, Crockatt J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. *J Clin Psychopharmacol* 2000;20:467–71.
66. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. *J Clin Psychopharmacol* 1999;19:341–8.
67. Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. *J Clin Psychopharmacol* 2003;23:240–9.

68. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. *Am J Psychiatry* 2006;163:1161–72.
69. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. *Am J Psychiatry* 2006;163:1531–41; quiz 1666.
70. Rush AJ. STAR*D: what have we learned? *Am J Psychiatry* 2007;164:201–4.
71. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. *Am J Psychiatry* 2006;163:1905–17.
72. Stein MB, Kline NA, Matloff JL. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. *Am J Psychiatry* 2002;159:1777–9.
73. Pollack MH, Simon NM, Zalta AK, et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. *Biol Psychiatry* 2006;59:211–5.
74. Rothbaum BO, Killeen TK, Davidson JR, Brady KT, Connor KM, Heekin MH. Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. *J Clin Psychiatry* 2008;69:520–5.

Appendix 1

Anxiety: “Have you . . .”

- Had a spell or attack where all of a sudden you felt frightened, anxious, or uneasy? (Panic)
- Been bothered by nerves or feeling anxious or on edge for 6 months? (GAD)
- Had a problem being anxious or uncomfortable around people? (SAD)
- Had recurrent dreams or nightmares of trauma or avoidance of trauma reminders? (PTSD)

Depression: “Over the past 2 weeks, have you . . .”

- Felt down depressed or hopeless felt little interest or pleasure in doing things?

Alcohol Problems:

“In the past year . . .”	0	1	2	3	4	
1) How often did you have a drink containing alcohol?	Never	Monthly or less	2–4 times a month	2–3 times a week	≥4 times a week	
2) How many drinks containing alcohol did you have on a typical day when you were drinking?	1 or 2	3 or 4	5 or 6	7–9	≥10	N/A (If #1 = 0)
3) How often did you have 6 or more (≥4 for women) drinks on one occasion?	Never	Less than monthly	Monthly	Weekly	Daily or almost daily	N/A (If #1 = 0)

Pain:

- On a scale of 0 to 10, where 0 means no pain and 10 means the worst pain imaginable, how would you rate your pain?

Appendix 2

Overall Anxiety Severity and Impairment Scale (OASIS)

1. In the past week, how often have you felt anxious?

- 0 = *No anxiety* in the past week.
- 1 = *Infrequent anxiety*. Felt anxious a few times.
- 2 = *Occasional anxiety*. Felt anxious as much of the time as not. It was hard to relax.
- 3 = *Frequent anxiety*. Felt anxious most of the time. It was very difficult to relax.
- 4 = *Constant anxiety*. Felt anxious all of the time and never really relaxed.

2. In the past week, when you have felt anxious, how intense or severe was your anxiety?

- 0 = *Little or none*. Anxiety was absent or barely noticeable.
- 1 = *Mild*. Anxiety was at a low level. It was possible to relax when I tried. Physical symptoms were only slightly uncomfortable.
- 2 = *Moderate*. Anxiety was distressing at times. It was hard to relax or concentrate, but I could do it if I tried. Physical symptoms were uncomfortable.
- 3 = *Severe*. Anxiety was intense much of the time. It was very difficult to relax or focus on anything else. Physical symptoms were extremely uncomfortable.
- 4 = *Extreme*. Anxiety was overwhelming. It was impossible to relax at all. Physical symptoms were unbearable.

3. In the past week, how often did you avoid situations, places, objects, or activities because of anxiety or fear?

- 0 = *None*. I do not avoid places, situations, activities, or things because of fear.
- 1 = *Infrequent*. I avoid something once in a while, but will usually face the situation or confront the object. My lifestyle is not affected.
- 2 = *Occasional*. I have some fear of certain situations, places, or objects, but it is still manageable. My lifestyle has only changed in minor ways. I always or almost always avoid the things I fear when I'm alone, but can handle them if someone comes with me.
- 3 = *Frequent*. I have considerable fear and really try to avoid the things that frighten me. I have made significant changes in my life style to avoid the object, situation, activity, or place.
- 4 = *All the Time*. Avoiding objects, situations, activities, or places has taken over my life. My lifestyle has been extensively affected and I no longer do things that I used to enjoy.

4. In the past week, how much did your anxiety interfere with your ability to do the things you needed to do at work, at school, or at home?

- 0 = *None*. No interference at work/home/school from anxiety.
- 1 = *Mild*. My anxiety has caused some interference at work/home/school. Things are more difficult, but everything that needs to be done is still getting done.
- 2 = *Moderate*. My anxiety definitely interferes with tasks. Most things are still getting done, but few things are being done as well as in the past.
- 3 = *Severe*. My anxiety has really changed my ability to get things done. Some tasks are still being done, but many things are not. My performance has definitely suffered.
- 4 = *Extreme*. My anxiety has become incapacitating. I am unable to complete tasks and have had to leave school, have quit or been fired from my job, or have been unable to complete tasks at home and have faced consequences like bill collectors, eviction, etc.

5. In the past week, how much has anxiety interfered with your social life and relationships?

- 0 = *None*. My anxiety doesn't affect my relationships.
 - 1 = *Mild*. My anxiety slightly interferes with my relationships. Some of my friendships and other relationships have suffered, but, overall, my social life is still fulfilling.
 - 2 = *Moderate*. I have experienced some interference with my social life, but I still have a few close relationships. I don't spend as much time with others as in the past, but I still socialize sometimes.
 - 3 = *Severe*. My friendships and other relationships have suffered a lot because of anxiety. I do not enjoy social activities. I socialize very little.
 - 4 = *Extreme*. My anxiety has completely disrupted my social activities. All of my relationships have suffered or ended. My family life is extremely strained.
-